CPMP recommends Novartis' Zometa

The EMEA's Committee for Proprietary Medicinal Products (CPMP) recommended approval for Novartis' Zometa zoledronic acid, an intravenous bisphosphonate to treat tumor-induced hypercalcemia. Novartis (...